Streetbeat News

Stock Prices

PEPEUSD

SPY

The crypto community is excited about Pepe (PEPE) as traders predict it may retest all-time highs this week. Key support/resistance level is $0.00905. PEPE added 530 new holders, totaling 220,672. Whale movements and institutional holdings are significant. PEPE is currently trading at $0.000009518, up 5% in 24 hours.

Portfolio Pulse from Khyathi Dalal

May 20, 2024 | 6:33 pm

KRRO

Korro presented additional preclinical data for KRRO-110 at the American Thoracic Society 2024 International Conference. KRRO-110 demonstrated sustained editing efficiency and significantly increased alpha-1 antitrypsin protein levels in a genetic AATD mouse model.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 6:33 pm

GL

Globe Life's CEO and Co-Chairman, James Darden, purchased 2,000 shares of the company's common stock at $84.82 per share, according to an SEC Form 4 filing.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 6:31 pm

AKTS

JAGX

MIRA

MMV

NKGN

SOHU

VIRI

U.S. stocks traded mixed with the Dow Jones falling over 150 points. Sohu.com reported a Q1 loss, missing analyst estimates. NKGen Biotech, MIRA Pharmaceuticals, and MultiMetaVerse Holdings saw significant stock price increases, while Virios Therapeutics, Akoustis Technologies, and Jaguar Health experienced sharp declines.

Portfolio Pulse from Avi Kapoor

May 20, 2024 | 6:31 pm

AAL

Financial giants have made a bearish move on American Airlines Group (NASDAQ:AAL) with 77% of options trades being bearish. The stock is currently trading at $14.43, down by 2.04%. Analysts have mixed ratings with target prices ranging from $17 to $22.

Portfolio Pulse from Benzinga Insights

May 20, 2024 | 6:31 pm

AEM

Financial giants have shown a bullish trend in the options market for Agnico Eagle Mines (NYSE:AEM), with 55% of traders being bullish. The price target for AEM ranges from $45.0 to $80.0, and the stock is currently trading at $70.0. The next earnings report is due in 65 days, and Citigroup maintains a Buy rating with a target price of $80.

Portfolio Pulse from Benzinga Insights

May 20, 2024 | 6:31 pm

ALB

Albemarle (NYSE:ALB) has outperformed the market over the past 20 years, producing an average annual return of 11.53%. A $100 investment in ALB 20 years ago would be worth $892.08 today. The article highlights the impact of compounded returns over time.

Portfolio Pulse from Benzinga Insights

May 20, 2024 | 6:30 pm

CME

CME Group (NASDAQ:CME) has significantly outperformed the market over the past 20 years, delivering an average annual return of 11.04%. A $100 investment in CME 20 years ago would be worth $813.50 today. The article highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

May 20, 2024 | 6:30 pm

LOAR

Loar Holdings (NYSE: LOAR) received favorable analyst coverage from Morgan Stanley, RBC Capital, and Citigroup following its IPO last month. The company, which operates in the aerospace and defense sector, reported strong financial results and has projected positive growth for fiscal-year 2024.

Portfolio Pulse from Vaishali Prayag

May 20, 2024 | 6:30 pm

ESPR

Esperion Therapeutics and Otsuka Pharmaceutical announced that their partnered cholesterol drug, bempedoic acid, achieved the primary endpoint in a Phase 3 trial in Japan. The trial showed statistically significant positive outcomes for patients with high LDL cholesterol. Otsuka plans to submit a New Drug Application in Japan in late 2024. Additionally, Esperion received a U.S. Patent Term Extension for bempedoic acid, extending its patent through December 2030. Following the news, Esperion's stock rose by 5.51%.

Portfolio Pulse from Vandana Singh

May 20, 2024 | 6:22 pm